SLC5A5 and neoplasm: Preclinical research utilizing xenograft tumor mouse models has shown the potential of CMV (cytomegalovirus) promoter-driven MSC-mediated NIS gene delivery, with successful selective NIS expression in tumors and metastases as well as a strong therapeutic response following [131I]NaI application [45].